CA2513287A1 - Ligands cibles - Google Patents

Ligands cibles Download PDF

Info

Publication number
CA2513287A1
CA2513287A1 CA002513287A CA2513287A CA2513287A1 CA 2513287 A1 CA2513287 A1 CA 2513287A1 CA 002513287 A CA002513287 A CA 002513287A CA 2513287 A CA2513287 A CA 2513287A CA 2513287 A1 CA2513287 A1 CA 2513287A1
Authority
CA
Canada
Prior art keywords
ligand
moiety
target
affinity
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513287A
Other languages
English (en)
Inventor
William Herman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2002/000317 external-priority patent/WO2002072141A2/fr
Priority claimed from CA 2397169 external-priority patent/CA2397169A1/fr
Priority claimed from CA 2402930 external-priority patent/CA2402930A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002513287A priority Critical patent/CA2513287A1/fr
Publication of CA2513287A1 publication Critical patent/CA2513287A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002513287A 2002-01-14 2003-01-14 Ligands cibles Abandoned CA2513287A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002513287A CA2513287A1 (fr) 2002-01-14 2003-01-14 Ligands cibles

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CA2,368,708 2002-01-14
CA2368708 2002-01-14
CAPCT/CA02/00317 2002-03-11
PCT/CA2002/000317 WO2002072141A2 (fr) 2001-03-09 2002-03-11 Ligands cibles
CA2,397,169 2002-08-13
CA 2397169 CA2397169A1 (fr) 2002-08-13 2002-08-13 Ligands cibles
CA2,402,930 2002-09-19
CA 2402930 CA2402930A1 (fr) 2002-09-19 2002-09-19 Ligands cibles
CA002513287A CA2513287A1 (fr) 2002-01-14 2003-01-14 Ligands cibles
PCT/CA2003/000044 WO2003057732A2 (fr) 2002-01-14 2003-01-14 Ligands cibles

Publications (1)

Publication Number Publication Date
CA2513287A1 true CA2513287A1 (fr) 2003-07-17

Family

ID=27426779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002513287A Abandoned CA2513287A1 (fr) 2002-01-14 2003-01-14 Ligands cibles

Country Status (4)

Country Link
EP (1) EP1497331A2 (fr)
AU (1) AU2003201559A1 (fr)
CA (1) CA2513287A1 (fr)
WO (1) WO2003057732A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841787A2 (fr) 2005-01-25 2007-10-10 Cell Therapeutics, Inc. Conjugues de proteine biologiquement actives possedant une demi-vie in vivo modifiee
EP3634999A1 (fr) * 2017-06-07 2020-04-15 Philogen S.p.A. Protéines de fusion d'anticorps anti-facteur de croissance endothéliale vasculaire/anti-fibronectine
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739904A1 (fr) * 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
AU658374B2 (en) * 1990-09-14 1995-04-13 Biosite Diagnostics Incorporated Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
AU729515B2 (en) * 1996-10-17 2001-02-01 Immunomedics Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
AU2226799A (en) * 1998-01-15 1999-08-02 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
WO2000018806A1 (fr) * 1998-09-25 2000-04-06 Horst Lindhofer Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles
EP1289564B1 (fr) * 2000-06-05 2018-07-18 Altor BioScience Corporation Fusions et conjugues de recepteurs de lymphocytes t et procedes d'utilisation correspondants
EP1455820A2 (fr) * 2001-03-09 2004-09-15 William Herman Ligands cibles

Also Published As

Publication number Publication date
WO2003057732A3 (fr) 2003-10-02
AU2003201559A1 (en) 2003-07-24
WO2003057732A2 (fr) 2003-07-17
AU2003201559A8 (en) 2003-07-24
EP1497331A2 (fr) 2005-01-19

Similar Documents

Publication Publication Date Title
US20050118164A1 (en) Targeted ligands
US20050069549A1 (en) Targeted ligands
US20050142539A1 (en) Targeted ligands
JP7256348B2 (ja) Ｃｔｌａ４に対する単一ドメイン抗体及びその誘導タンパク質
CN112789294A (zh) 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
JP6929951B2 (ja) 抗ｌａｇ−３抗体およびその使用
US11091546B2 (en) Optimized PNE-based chimeric receptor T cell switches and uses thereof
JP6873901B2 (ja) Ｔｎｆファミリーリガンド三量体を含む抗原結合分子
CN104114578B (zh) Bcma和cd3的结合分子
JP2020531438A (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｈｌａ−ｅ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質
TW201945390A (zh) 靶向cd33之抗體可變域及其用途
US20210277141A1 (en) Anti-PSMA Antibodies and Use Thereof
TW201942134A (zh) 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
KR20180098672A (ko) 자가-가교결합 항체
US20230167185A1 (en) Cd40 binding protein
CN109929037B (zh) 针对程序性死亡配体的结合物及其应用
WO2019195408A1 (fr) Domaines variables d'anticorps ciblant les dll3, et leur utilisation
BR112021007995A2 (pt) molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente
CA2414148A1 (fr) Ligands cibles
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
CA2513287A1 (fr) Ligands cibles
US20210163590A1 (en) Novel anti-tim-3 antibodies
CA2402930A1 (fr) Ligands cibles
CA2479116A1 (fr) Ligands cibles
CA2441653A1 (fr) Ligands cibles

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued